Allergy Therapeutics
Allergy Therapeutics, a leading specialist in allergy immunotherapy, is headquartered in the United Kingdom and operates extensively across Europe and North America. Founded in 2003, the company has established itself as a pioneer in the development of innovative allergy treatments, focusing on both the diagnosis and management of allergic conditions. The firm’s core offerings include a range of allergy vaccines and immunotherapy products, distinguished by their unique formulations and patient-centric approach. Allergy Therapeutics is committed to advancing the field of allergy treatment, evidenced by its robust pipeline and significant clinical milestones. With a strong market position, the company continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by allergies.
DitchCarbon Score
How does Allergy Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergy Therapeutics's score of 15 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Allergy Therapeutics's reported carbon emissions
In 2023, Allergy Therapeutics reported total carbon emissions of approximately 4,291,000 kg CO2e. This figure includes 431,000 kg CO2e from Scope 1 emissions, which primarily consist of direct emissions from owned or controlled sources. Scope 2 emissions, related to purchased electricity and steam, accounted for about 1,901,000 kg CO2e, while Scope 3 emissions, which include indirect emissions such as business travel, totalled approximately 1,959,000 kg CO2e. Comparatively, in 2022, the company’s total emissions were about 4,040,000 kg CO2e, indicating a slight increase in emissions year-on-year. The breakdown for 2022 included 437,000 kg CO2e from Scope 1, 1,742,000 kg CO2e from Scope 2, and 1,861,000 kg CO2e from Scope 3. Despite these figures, Allergy Therapeutics has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, Allergy Therapeutics will likely need to establish clear climate commitments to align with global efforts to mitigate climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 25,000 | 000,000 | 000,000 |
| Scope 2 | 2,257,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 614,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergy Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
